Abstract 2127P
Background
Yoga has gained more attention worldwide in the last decade and shown the potential to improve physiological and psychological health in various disease conditions. Studies on breast cancer (BC) survivors showed mild to moderate effects within one-month to six-month on various parameters. Cancer treatment-related side effects are often related with functional as well as symptomatic scales. Therefore, we have conducted a randomized control study to find out the effect of long-term yogic intervention on symptom and functional scale in patients undergoing treatment.
Methods
This study was approved by the institutional ethics committee. The current study consisted of 96 BC stage II/III patients receiving cancer treatments who were randomly divided into two groups: Group-I (non-yoga) and Group-II (yoga). Group-II was advised to perform yoga 5 days per week for 48 weeks and was monitored regularly by video or phone calls. At different time points (T0 (baseline), T1 (16th week), T2 (32nd week), and T3 (48th week), we collected the breast cancer specific questionnaire (EORTC-BR23), which consisted of various functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and symptomatic scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss), and compared them between groups as well as within group.
Results
Out of 96 total patients, 82 were analyzed for T0-T3 (40 in group-I and 42 in group-II). In groups I and II, the mean age was 47.67±11.68 and 43.11±9.39, respectively. Yogic intervention resulted in a significant improvement in arm symptoms and side effects from T0 to T3 (p<0.001) and T1 to T3 (p<0.01) in group II, while group I also improved from T0 to T3 (p<0.05). The most significant difference was observed in Group-I (T0) vs. Group-II (T3). There was no significant difference observed in upset by hair loss, body image, breast symptoms, or future perspective.
Conclusions
The duration of yoga positively correlated with the systematic therapy side effects and improved their arm symptoms. This suggested that yogic intervention during therapy could be an effective complementary therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06